Department of Medicine, Columbia University Irving Medical Center, 650 West 168th Street, Black Building 8-816, New York, NY 10032, USA.
College of Physicians and Surgeons, Columbia University Irving Medical Center, 650 West 168th Street, Black Building 8-816, New York, NY 10032, USA.
Hematol Oncol Clin North Am. 2019 Apr;33(2):291-299. doi: 10.1016/j.hoc.2018.12.005. Epub 2019 Jan 17.
Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8 tumor-infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key.
免疫疗法极大地改善了许多癌症患者的预后，但也会导致严重的免疫相关不良反应。因此，生物标志物对于帮助临床医生权衡免疫疗法的潜在益处及其潜在毒性至关重要，生物标志物是指能够指示患者疾病结局或对治疗反应的分子标记物。免疫组织化学（IHC）迄今为止一直是发现和使用生物标志物（如 CD8 肿瘤浸润淋巴细胞）的强大技术。然而，IHC 的重复性有限。因此，如果要将更多基于 IHC 的生物标志物推向临床，使用多重化或自动化技术对该技术进行改进是关键。
